Across TCGA pan-cancer cohorts, NELFE Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated NELFE data layer compared with 25 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher NELFE Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NELFE expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

ACC, STAD, and PRAD are the cancer types where NELFE Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.066	0.667	.002	12	view →
STAD	OS	Median	II,III,IV	0.183	0.660	.009	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	II,III,IV	0.605	0.211	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: NELFE tumor-vs-normal RNA expression · all NELFE data types